CoChat

Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens

Montazeri, Hesam, Coto-Llerena, Mairene, Bianco, Gaia, Zangene, Ehsan, Taha-Mehlitz, Stephanie, Paradiso, Viola, Srivatsa, Sumana, de Weck, Antoine, Roma, Guglielmo, Lanzafame, Manuela, Bolli, Martin, Beerenwinkel, Niko, von Flüe, Markus, Terracciano, Luigi M, Piscuoglio, Salvatore, Ng, Charlotte K Y · 2021 · Nucleic Acids Research

Published version of a preprint

Cited by 13

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Systematic perturbation screens provide comprehensive resources for the elucidation of cancer driver genes. The perturbation of many genes in relatively few cell lines in such functional screens necessitates the development of specialized computational tools with sufficient statistical power. Here we developed APSiC (Analysis of Perturbation Screens for identifying novel Cancer genes) to identify genetic drivers and effectors in perturbation screens even with few samples. Applying APSiC to the shRNA screen Project DRIVE, APSiC identified well-known and novel putative mutational and amplified cancer genes across all cancer types and in specific cancer types. Additionally, APSiC discovered tumor-promoting and tumor-suppressive effectors, respectively, for individual cancer types, including genes involved in cell cycle control, Wnt/β-catenin and hippo signalling pathways. We functionally demonstrated that LRRC4B, a putative novel tumor-suppressive effector, suppresses proliferation by delaying cell cycle and modulates apoptosis in breast cancer. We demonstrate APSiC is a robust statistical framework for discovery of novel cancer genes through analysis of large-scale perturbation screens. The analysis of DRIVE using APSiC is provided as a web portal and represents a valuable resource for the discovery of novel cancer genes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkab627

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 69

  1. Marcotte, 2012, Essential gene profiles in breast, pancreatic, and ovarian cancer cells, Cancer Discov., 2, 172, 10.1158/2159-8290.CD-11-0224 · DOI · Paper page
  2. Meyers, 2017, Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells, Nat. Genet., 49, 1779, 10.1038/ng.3984 · DOI · Paper page
  3. Marcotte, 2016, Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance, Cell, 164, 293, 10.1016/j.cell.2015.11.062 · DOI · Paper page
  4. Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 · DOI · Paper page
  5. Bailey, 2018, Comprehensive characterization of cancer driver genes and mutations, Cell, 173, 371, 10.1016/j.cell.2018.02.060 · DOI · Paper page
  6. Martínez-Jiménez, 2020, A compendium of mutational cancer driver genes, Nat. Rev. Cancer, 20, 555, 10.1038/s41568-020-0290-x · DOI · Paper page
  7. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  8. Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
  9. Schmich, 2015, gespeR: a statistical model for deconvoluting off-target-confounded RNA interference screens, Genome Biol., 16, 220, 10.1186/s13059-015-0783-1 · DOI
  10. Shao, 2013, ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens, Genome Res., 23, 665, 10.1101/gr.143586.112 · DOI · Paper page
  11. König, 2007, A probability-based approach for the analysis of large-scale RNAi screens, Nat. Methods, 4, 847, 10.1038/nmeth1089 · DOI · Paper page
  12. McFarland, 2018, Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration, Nat. Commun., 9, 4610, 10.1038/s41467-018-06916-5 · DOI · Paper page
  13. Szczurek, 2013, Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma, Int. J. Cancer, 133, 2123, 10.1002/ijc.28235 · DOI
  14. Jerby-Arnon, 2014, Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality, Cell, 158, 1199, 10.1016/j.cell.2014.07.027 · DOI · Paper page
  15. Sinha, 2017, Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data, Nat. Commun., 8, 15580, 10.1038/ncomms15580 · DOI
  16. Sahoo, 2008, Boolean implication networks derived from large scale, whole genome microarray datasets, Genome Biol., 9, R157, 10.1186/gb-2008-9-10-r157 · DOI · Paper page
  17. Sinha, 2014, Mining TCGA data using Boolean implications, PLoS One, 9, e102119, 10.1371/journal.pone.0102119 · DOI
  18. Srivatsa, 2019, Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens, 10.1101/810374 · DOI
  19. Ghandi, 2019, Next-generation characterization of the Cancer Cell Line Encyclopedia, Nature, 569, 503, 10.1038/s41586-019-1186-3 · DOI · Paper page
  20. Kamgar-Parsi, 1995, Distribution and moments of the weighted sum of uniforms random variables, with applications in reducing monte carlo simulations, J. Statist. Comput. Simulation, 52, 399, 10.1080/00949659508811688 · DOI
  21. Colaprico, 2016, TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data, Nucleic Acids Res., 44, e71, 10.1093/nar/gkv1507 · DOI · Paper page
  22. Ramos, 2020, Multiomic integration of public oncology databases in bioconductor, JCO Clin. Cancer Inform., 4, 958, 10.1200/CCI.19.00119 · DOI
  23. Hart, 2013, Finding the active genes in deep RNA-seq gene expression studies, BMC Genomics, 14, 778, 10.1186/1471-2164-14-778 · DOI · Paper page
  24. Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol., 12, R41, 10.1186/gb-2011-12-4-r41 · DOI · Paper page
  25. Anderson, 2008, Experimental validation of the importance of seed complement frequency to siRNA specificity, RNA, 14, 853, 10.1261/rna.704708 · DOI · Paper page
  26. Jackson, 2006, Position-specific chemical modification of siRNAs reduces ‘off-target’ transcript silencing, RNA, 12, 1197, 10.1261/rna.30706 · DOI · Paper page
  27. Tang, 2019, LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function, Nat. Commun., 10, 5755, 10.1038/s41467-019-13591-7 · DOI
  28. Andreozzi, 2016, HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models, Neoplasia, 18, 724, 10.1016/j.neo.2016.10.002 · DOI
  29. Pilco-Ferreto, 2016, Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines, Int. J. Oncol., 49, 753, 10.3892/ijo.2016.3558 · DOI · Paper page
  30. Inao, 2018, Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin, Oncotarget, 9, 25545, 10.18632/oncotarget.25370 · DOI
  31. Dimitrakopoulos, 2018, Network-based integration of multi-omics data for prioritizing cancer genes, Bioinformatics, 34, 2441, 10.1093/bioinformatics/bty148 · DOI · Paper page
  32. Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
  33. Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
  34. Shuai, 2020, Combined burden and functional impact tests for cancer driver discovery using DriverPower, Nat. Commun., 11, 734, 10.1038/s41467-019-13929-1 · DOI · Paper page
  35. Chakravarty, 2017, OncoKB: A precision oncology knowledge base, JCO Precis Oncol, 2017, PO.17.00011
  36. Kim, 2016, Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers, Nat. Commun., 7, 12991, 10.1038/ncomms12991 · DOI
  37. Kim, 2016, Amplification of TLK2 induces genomic instability via impairing the G2-M checkpoint, Mol. Cancer Res., 14, 920, 10.1158/1541-7786.MCR-16-0161 · DOI
  38. Johnson, 2018, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol., 15, 234, 10.1038/nrclinonc.2018.8 · DOI · Paper page
  39. He, 2013, Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling, Cell, 155, 384, 10.1016/j.cell.2013.09.031 · DOI · Paper page
  40. Tchirkov, 2007, Interleukin-6 gene amplification and shortened survival in glioblastoma patients, Br. J. Cancer, 96, 474, 10.1038/sj.bjc.6603586 · DOI
  41. Arnedo-Pac, 2019, OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers, Bioinformatics, 35, 5396, 10.1093/bioinformatics/btz588 · DOI
  42. Gao, 2017, 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets, Genome Med., 9, 4, 10.1186/s13073-016-0393-x · DOI · Paper page
  43. Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
  44. Kent, 2013, RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets, Oncogene, 32, 2576, 10.1038/onc.2012.266 · DOI
  45. Wang, 2011, Human SBK1 is dysregulated in multiple cancers and promotes survival of ovary cancer SK-OV-3 cells, Mol. Biol. Rep., 38, 3551, 10.1007/s11033-010-0465-8 · DOI
  46. Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 · DOI · Paper page
  47. Pollock, 2007, Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes, Oncogene, 26, 7158, 10.1038/sj.onc.1210529 · DOI · Paper page
  48. Pérez de Castro, 2007, A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy, Carcinogenesis, 28, 899, 10.1093/carcin/bgm019 · DOI · Paper page
  49. Malumbres, 2014, Cyclin-dependent kinases, Genome Biol., 15, 122, 10.1186/gb4184 · DOI · Paper page
  50. Mueller, 2015, WEE1 kinase as a target for cancer therapy, J. Clin. Oncol., 33, 3485, 10.1200/JCO.2015.62.2290 · DOI
  51. Kazanietz, 2017, The Rac GTPase in cancer: from old concepts to new paradigms, Cancer Res., 77, 5445, 10.1158/0008-5472.CAN-17-1456 · DOI · Paper page
  52. Morgan, 2018, Targeting LGR5 in colorectal cancer: therapeutic gold or too plastic?, Br. J. Cancer, 118, 1410, 10.1038/s41416-018-0118-6 · DOI
  53. Calses, 2019, Hippo pathway in cancer: aberrant regulation and therapeutic opportunities, Trends Cancer Res., 5, 297, 10.1016/j.trecan.2019.04.001 · DOI · Paper page
  54. Perra, 2014, YAP activation is an early event and a potential therapeutic target in liver cancer development, J. Hepatol., 61, 1088, 10.1016/j.jhep.2014.06.033 · DOI · Paper page
  55. Okino, 2006, Inactivation of Crk SH3 domain-binding guanine nucleotide-releasing factor (C3G) in cervical squamous cell carcinoma, Int. J. Gynecol. Cancer, 16, 763, 10.1111/j.1525-1438.2006.00352.x · DOI
  56. Wu, 2006, LRRC4, a putative tumor suppressor gene, requires a functional leucine-rich repeat cassette domain to inhibit proliferation of glioma cells in vitro by modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-kappaB pathway, Mol. Biol. Cell, 17, 3534, 10.1091/mbc.e05-11-1082 · DOI
  57. Zhang, 2005, Study of a novel brain relatively specific gene LRRC4 involved in glioma tumorigenesis suppression using the Tet-on system, Acta Biochim. Biophys. Sin., 37, 532, 10.1111/j.1745-7270.2005.00079.x · DOI
  58. Wang, 2011, LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization, J. Cell. Biochem., 112, 3621, 10.1002/jcb.23293 · doi:10.1002/jcb.23293
  59. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  60. Schulz-Heddergott, 2018, Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion, Cancer Cell, 34, 298, 10.1016/j.ccell.2018.07.004 · DOI · Paper page
  61. Harjes, 2019, Nothing to gain for p53, Nat. Rev. Cancer, 19, 544, 10.1038/s41568-019-0202-0 · DOI
  62. Rubinstein, 2019, APC mutational patterns in gastric adenocarcinoma are enriched for missense variants with associated decreased survival, Genes Chromosomes Cancer
  63. Yamaguchi, 2018, Identification and characterization of a novel adenomatous polyposis coli mutation in adult pancreatoblastoma, Oncotarget, 9, 10818, 10.18632/oncotarget.24017 · DOI
  64. Taha-Mehlitz, 2021, Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis, Theranostics, 11, 4011, 10.7150/thno.50051 · DOI
  65. Aguirre, 2016, Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting, Cancer Discov., 6, 914, 10.1158/2159-8290.CD-16-0154 · DOI · Paper page
  66. Dogruluk, 2015, Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations, Cancer Res., 75, 5341, 10.1158/0008-5472.CAN-15-1654 · DOI · Paper page
  67. Zhang, 2008, Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells, Breast Cancer Res. Treat., 112, 217, 10.1007/s10549-007-9847-6 · DOI
  68. Li, 2019, The landscape of cancer cell line metabolism, Nat. Med., 25, 850, 10.1038/s41591-019-0404-8 · DOI · Paper page
  69. Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page

Cited by

Metadata

Authors
Montazeri, H., Coto-Llerena, M., Bianco, G., Zangene, E., Taha-Mehlitz, S., Paradiso, V., Srivatsa, S., de Weck, A., Roma, G., Lanzafame, M., Bolli, M., Beerenwinkel, N., von Flüe, M., Terracciano, L. M., Piscuoglio, S., & Ng, C. K. Y.
Affiliations
  • Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
  • Visceral Surgery and Precision Medicine Research laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland
  • Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
  • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
  • Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Switzerland
  • Department of Pathology, Humanitas Clinical and Research Center, IRCCS, Milan, Italy
Venue
Nucleic Acids Research
Published
2021-07-27
Volume
49
Issue
15
Pages
8488-8504
ISSN
  • 0305-1048
  • 1362-4962
Cited by
13
References
15
Language
en
Funders
  • Swiss Cancer League (KFS-4988-02-2020-R, KFS-4543-08-2018)
  • Swiss National Science Foundation (PZ00P3_168165)
  • AIRC (IG 2019)
  • European Research Council (609883)
  • Theron Foundation, Vaduz

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.